Akamis Bio
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Akamis Bio sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Akamis Bio: 6 sponsored US clinical trials, 1 recruiting.
Akamis Bio sponsors 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Epithelial Tumor, with 2 trials.
Upper-quartile sponsor footprint
Akamis Bio sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
NCT06459869
Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)
NCT05165433
Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours
NCT05043714
First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector
NCT04053283
First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)
NCT03852511
Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors
NCT02636036
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
What is open in the Akamis Bio pipeline
1 recruiting of 6 indexed (17% open); 5 completed (83%).
Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Epithelial Tumor (2 trials), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Akamis Bio: open-pipeline peers nationwide
Peers matched on 6 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Akamis Bio sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
- Angiodynamics · 17% recruiting · 12 trials
- Anthos Therapeutics · 17% recruiting · 6 trials
Related
What to do with this Akamis Bio page
6 registered trials is a research-attention snapshot, not an endorsement of Akamis Bio or any single study.
- 1 of Akamis Bio's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Epithelial Tumor is the condition Akamis Bio studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Epithelial Tumor trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Akamis Bio pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.